List of Intrarosa drug patents
Intrarosa is owned by Millicent.
Intrarosa contains Prasterone.
Intrarosa has a total of 3 drug patents out of which 0 drug patents have expired.
Intrarosa was authorised for market use on 16 November, 2016.
Intrarosa is available in insert;vaginal dosage forms.
Intrarosa can be used as intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
The generics of Intrarosa are possible to be released after 19 March, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629129 | MILLICENT | Pharmaceutical compositions |
Aug, 2028
(5 years from now) | |
| US8957054 | MILLICENT | Pharmaceutical compositions |
Jan, 2030
(6 years from now) | |
| US8268806 | MILLICENT | Pharmaceutical compositions |
Mar, 2031
(8 years from now) | |
Drugs and Companies using PRASTERONE ingredient
Market Authorisation Date: 16 November, 2016
Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Dosage: INSERT;VAGINAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic